Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.53 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CPN1 | P15169 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7319341 | 1.00 | CYP2C19 (0.57) | CYP2C19GABBR2GABBR1TAAR1HTR2A | |
| SCHEMBL197934 | 1.00 | CYP2C19 (0.57) | CYP2C19GABBR2GABBR1TAAR1HTR2A | |
| Hydrochloric Acid SCHEMBL7609245 | 0.98 | CYP2C19 (0.55) | CYP2C19GABBR2GABBR1TAAR1HTR2A | |
| SCHEMBL28332935 | 0.91 | CPN1 (0.48) | CYP2C19GABBR2GABBR1EPHX1CYP2D6 | |
| SCHEMBL27543440 | 0.89 | PTGS2 (0.55) | CYP2C19GABBR2GABBR1TAAR1HTR2A | |
| SCHEMBL1310192 | 0.88 | CHRNB2 (0.57) | CYP2C19GABBR2GABBR1 | |
| SCHEMBL27582649 | 0.86 | GABBR2 (0.53) | CYP2C19GABBR2GABBR1TAAR1HTR2A | |
| SCHEMBL637030 | 0.84 | EPHX1 (0.66) | CYP2C19GABBR2GABBR1TAAR1HTR2A | |
| SCHEMBL12323888 | 0.84 | EPHX1 (0.66) | CYP2C19GABBR2GABBR1TAAR1HTR2A | |
| SCHEMBL11136320 | 0.83 | CYP2C19 (0.40) | CYP2C19GABBR2GABBR1EPHX1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281149-B2 | Modulators of G-protein coupled receptors | CARMOT THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| CN-109790114-B | Novel chiral ligand, metal chelate, various unnatural amino acids and synthesis method of maraviroc and key intermediate thereof | 中国科学院上海药物研究所 | 2025-03-07 | — | — | CN | disclosed |
| US-20240383960-A1 | Modulators of G-Protein Coupled Receptors | CARMOT THERAPEUTICS INC. (US) | 2024-11-21 | — | — | US | disclosed |
| CN-117980325-A | Modulators of G-protein coupled receptors | 卡莫特治疗学股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-4337682-A2 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | Carmot Therapeutics Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20230151074-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| WO-2022241287-A2 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| WO-2021067439-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| CN-107793351-B | Beta-amino acid synthesis method and beta-amino acid synthesized by same | 上海交通大学 | 2020-11-10 | — | — | CN | disclosed |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RAPAFUSYN PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-6417203-B1 | HETEROCYCLIC AMIDES | PFIZER INC. | 2002-07-09 | — | — | US | disclosed |
| US-6180627-B1 | INDOLE, INDAZOLE, BENZOTRIAZOLE AND BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2001-01-30 | — | — | US | disclosed |
| EP-0997474-A1 | Antithrombotic agents | PFIZER INC. (US) | 2000-05-03 | — | — | EP | disclosed |
| US-5102667-A | Antiallergens, antiinflammatory agents, nervous system disorders, immunology, psychological disorders | RHONE-POULENC SANTE (FR) | 1992-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383960-A1 | Modulators of G-Protein Coupled Receptors | GIPR, GLP1R, GCGR | CYP2C19 4614/4885GABBR2 636/4885GABBR1 837/4885 |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | CYP2C19 3397/4885GABBR2 2940/4885GABBR1 3135/4885 |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | CYP2C19 3397/4885GABBR2 2940/4885GABBR1 3135/4885 |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | CYP2C19 3397/4885GABBR2 2940/4885GABBR1 3135/4885 |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | CYP2C19 3397/4885GABBR2 2940/4885GABBR1 3135/4885 |
| US-12281149-B2 | Modulators of G-protein coupled receptors | GIPR, GLP1R, GCGR | CYP2C19 4624/4885GABBR2 511/4885GABBR1 650/4885 |
| US-20230151074-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | GIPR, GLP1R, GCGR | CYP2C19 4624/4885GABBR2 511/4885GABBR1 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.